Intellectual Property Counsel Janet Linn was quoted in the Bloomberg Law article, “Virus Delays Stir Deadline Concerns in Generic Drug Patent Cases.”

The article discusses how the disruption to federal courts due to COVID-19 has affected generic drug patent cases, which have a 30-month stay on federal approval under the Hatch-Waxman Act.

As the limitations on travel and physical distancing policies impact the ability of attorneys to collect documents and depose witnesses, Janet notes, “that makes dealing with deadlines in federal courts difficult.”

Read here.